GlassScriptPhysician profile
Rene D Gonzalez
NPI 1699761650
$1,369.39
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $532.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $405.72 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.77 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $189.19 | 2019-2020 | |
| Mylan Specialty L.P. | $133.98 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $94.49 | 2019 | |
| Sunovion Pharmaceuticals INC. | $80.93 | 2019-2020 | |
| Genzyme Corporation | $60.22 | 2019 | |
| Insmed, INC. | $53.53 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $36.12 | 2020 | |
| Optinose US, INC. | $16.96 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.50 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.98 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.